Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features.


PURPOSE Despite significant progress in the molecular understanding of medulloblastoma, stratification of risk in patients remains a challenge. Focus has shifted from clinical parameters to molecular markers, such as expression of specific genes and selected genomic abnormalities, to improve accuracy of treatment outcome prediction. Here, we show how… (More)
DOI: 10.1200/JCO.2010.28.1675


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics